Skip to main content


Ongoing Private
Sector Projects

The following projects are currently being completed by DAS. Projects are listed in the order in which Research Ethics Board approval was obtained.

Client: Sunnybrook Research Institute/HOPE Research Centre

Project ID: P2020-078/2022 0970 259 000

Research Question/Objectives: The client is looking for Canadian specific costs of various resources associated with three types of cancers for a model that requires cost, outcomes, and patient inputs.

Cost, outcomes, and patient inputs and utilization rates of various resources will be identified for the following cohorts of cancers:

  • Breast cancer
  • Biliary tract cancer
  • Hepatocellular carcinoma.

Availability of Results: study in progress

Client: IQVIA Solutions Canada Inc.

Project ID: P2020-090 / 2021 0970 285 000

Research Question/Objectives: The purpose of this study is to describe the patient pathways for obesity management at hospital and/or specialized obesity services in Canada. Treatment patterns defined by the initiation, discontinuation, sequence, timing and duration of specific obesity interventions, as well as the concurrent healthcare resource utilization (HCRU) will be described for patients with body mass index (BMI) ≥30 kg/m2.

Research objectives:

  • Describe the real-world obesity care pathway for patients BMI ≥30 kg/m2, from their first obesity clinic visit to the end of follow up, by summarizing patients’ interactions with the healthcare system in Canada.
  • Describe key patient characteristics (e.g., BMI, age, presence of comorbidities, Charlson Comorbidity Index) at specialist entry of the obesity care pathway.
  • Describe what professionals (e.g., endocrinologists, surgeons, etc.) are involved in obesity management throughout the obesity care pathway.
  • Describe the frequency, timing and duration of obesity treatment received along the obesity care pathway, including initiation, stopping and retreatment patterns, for the following types of obesity interventions: lifestyle modifications, pharmacological interventions, bariatric endoscopy, bariatric surgery.
  • Describe HCRU throughout the obesity care pathway.
  • Describe the incidence of key obesity-related comorbidities along the obesity care pathway (including, but not limited to, pre diabetes, type 2 diabetes [T2D], cardiovascular disease [CVD], others).
  • If feasible, to evaluate the increase in HCRU and direct cost (assessed during follow-up) attributable to comorbidities, adjusting for relevant demographic and clinical characteristics (including BMI and changes in BMI over the follow-up period).
  • Subject to adequate sample size, study objectives (when applicable) will be evaluated separately for patients in obesity class I (BMI 30-35), class II (BMI 35-40) and class III (BMI 40-45) at entry of the pathway, patients with and without comorbidities of interest (independently for each comorbidity) and patients who did or did not undergo bariatric surgery/endoscopy during follow-up.

Availability of Results: In progress

Client: IQVIA Solutions Canada Inc.

Project ID: P2021-104/ 2023 0970 322 000

Research Question/Objectives: Migraine is a common neurological disease caused due to activation of the trigeminovascular system (TGVS) in the brain. Migraine was identified as being the 2nd leading cause of disability globally after low back pain. The overall migraine prevalence in the Canadian population was reported as 8.3% (2.7 million), in 2010/2011. As per the International Classification of Headache Disorders (ICHD-3), migraine can be classified into various subtypes, including episodic and chronic migraines (CM). There are acute and preventive treatments available for migraines. While acute treatment reverses the attack, preventive treatments are used to reduce severity and frequency of attacks in patients with severe migraine. Preventive medication helps in decreasing the overall cost burden and healthcare utilization associated with the migraine attack.

Research objectives:

  • Compare HCRU and cost of EM and CM patients using preventive medications with their respective matched non-migraine controls.
  • Describe HCRU and cost of EM and CM patients based on number of preventive medication classes they cycle through.
  • Describe HCRU and cost of EM and CM patients using preventive medications that are optimally managed vs. those that are sub-optimally managed.

Availability of Results: In progress